Acetazolamide Pregnancy and Breastfeeding Warnings
Acetazolamide Pregnancy Warnings
Despite widespread usage, there is no evidence of a direct association between acetazolamide and birth defects during human pregnancy. Two cases are noteworthy. In one, a woman who used acetazolamide 750 mg/day for glaucoma during the first and second trimesters gave birth to an infant with sacrococcygeal teratoma. In a second case, a woman who used acetazolamide 500 mg/day for glaucoma throughout pregnancy gave birth to an infant who demonstrated metabolic complications postpartum. These problems included metabolic acidosis, hyperbilirubinemia, hypocalcemia, and hypomagnesemia. The neonate was successfully treated, and was only observed to have mild hypertonicity of the lower limbs at up to eight months of age. Retrospective studies, such as the Collaborative Perinatal Project (CCP), reveal no evidence of a relationship between major or minor categories of defects to the use of acetazolamide. The CPP found 12 of 50,282 monitored mother-child pairs had been exposed to the drug during the first or second trimester. A total of 1,024 pairs were exposed to the drug during pregnancy. None of the 12 and 18 of the 1,024 were observed to have anomalies. The incidence of expected anomalies was 18.06 in the 1,024. Therefore, there is no evidence of teratogenicity associated with the use of acetazolamide from this retrospective study. Physicians are encouraged to register patients before fetal outcome is known (e.g., ultrasound, results of amniocentesis, etc) into the Antiepileptic Drug (AED) Pregnancy Registry at 1-888-233-2334 or 1-888-AED-AED4. This is an ongoing study at the Massachusetts General Hospital/Harvard Medical School. This study is designed to monitor the outcomes of pregnant women exposed to antiepileptic drugs in order to determine which therapies are associated with increased risk.
Acetazolamide has been assigned to pregnancy category C. Animal studies have shown it to be teratogenic (limb defects, axial skeletal and genitourinary malformations). There are no controlled data from human pregnancy. Acetazolamide should only be given during pregnancy when there are no alternatives and benefit outweighs risk.
Acetazolamide Breastfeeding Warnings
Acetazolamide is excreted into human milk in small amounts. Adverse effects in the nursing infant are unlikely. Acetazolamide is considered compatible with breast-feeding by the American Academy of Pediatrics.
Limited data are available. A single case of a woman who breast-fed while taking acetazolamide SR 1000 mg/day for glaucoma has been reported. Milk acetazolamide levels after 5 days between 1 and 9 hours after a dose ranged from 1.3 to 2.1 mcg/mL, which represented approximately 25% of the maternal serum drug levels. Plasma levels in the nursing infant ranged from 0.2 to 0.6 mcg/mL. No side effects in the nursing infant were observed. In short, limited data suggest that nursing infants are likely to receive only miniscule amounts of acetazolamide, amounts unlikely to result in side effects.
- Acetazolamide use while Breastfeeding (in more detail)
- acetazolamide Consumer Information
- Pregnancy Support Group
- FDA Pregnancy Categories
- Medicine use during Pregnancy
- Medicine use while Breastfeeding
- Safe Medications during Breastfeeding
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.